ChemR 23 to Regulate Inflammation Receptor BLT 1 and 4 Leukotriene B Resolvin E 1 Selectively Interacts with Elangovan

[1]  Anders Gabrielsen,et al.  Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[2]  J. Palmblad,et al.  Differential induction of BLT receptor expression on human endothelial cells by lipopolysaccharide, cytokines, and leukotriene B4. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[3]  L. Audoly,et al.  Neutrophil-derived leukotriene B4 is required for inflammatory arthritis , 2006, The Journal of experimental medicine.

[4]  B. Levy,et al.  RvE1 protects from local inflammation and osteoclastmediated bone destruction in periodontitis , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  Vilmundur Gudnason,et al.  A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction , 2006, Nature Genetics.

[6]  C. Clish,et al.  The contributions of aspirin and microbial oxygenase to the biosynthesis of anti-inflammatory resolvins: novel oxygenase products from omega-3 polyunsaturated fatty acids. , 2005, Biochemical and biophysical research communications.

[7]  G. Hansson,et al.  Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[8]  John Savill,et al.  Resolution of inflammation: the beginning programs the end , 2005, Nature Immunology.

[9]  C. Funk.  Leukotriene modifiers as potential therapeutics for cardiovascular disease , 2005, Nature Reviews Drug Discovery.

[10]  Makoto Arita,et al.  Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Charles N. Serhan,et al.  Molecular circuits of resolution: formation and actions of resolvins and protectins , 2005, The Journal of Immunology.

[12]  A. Sher,et al.  Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1 , 2005, The Journal of experimental medicine.

[13]  Shubhada Sankararaman,et al.  Cells, Tissues, and Disease: Principles of General Pathology , 2005 .

[14]  Jilly F. Evans,et al.  Leukotriene B4 Strongly Increases Monocyte Chemoattractant Protein-1 in Human Monocytes , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[15]  A. Lusis,et al.  Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. , 2004, The New England journal of medicine.

[16]  Adriano G. Rossi,et al.  Inflammatory Resolution: new opportunities for drug discovery , 2004, Nature Reviews Drug Discovery.

[17]  J. Gulcher,et al.  The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke , 2004, Nature Genetics.

[18]  J. Suttles,et al.  Role of Leukotriene B4 Receptors in the Development of Atherosclerosis: Potential Mechanisms , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[19]  Marc Parmentier,et al.  Specific Recruitment of Antigen-presenting Cells by Chemerin, a Novel Processed Ligand from Human Inflammatory Fluids , 2003, The Journal of experimental medicine.

[20]  R. Gerszten,et al.  Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment , 2003, Nature Immunology.

[21]  C. Serhan,et al.  Human ALX receptor regulates neutrophil recruitment in transgenic mice: roles in inflammation and host defense , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  Jilly F. Evans,et al.  International Union of Pharmacology XXXVII. Nomenclature for Leukotriene and Lipoxin Receptors , 2003, Pharmacological Reviews.

[23]  S. Marullo,et al.  Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor , 2002, Nature Medicine.

[24]  J. Manson,et al.  Blood levels of long-chain n-3 fatty acids and the risk of sudden death. , 2002, The New England journal of medicine.

[25]  C. Clish,et al.  Novel Functional Sets of Lipid-Derived Mediators with Antiinflammatory Actions Generated from Omega-3 Fatty Acids via Cyclooxygenase 2–Nonsteroidal Antiinflammatory Drugs and Transcellular Processing , 2000, The Journal of experimental medicine.

[26]  Takao Shimizu,et al.  A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. , 2000, The Journal of experimental medicine.

[27]  U. V. von Andrian,et al.  Bltr Mediates Leukotriene B4–Induced Chemotaxis and Adhesion and Plays a Dominant Role in Eosinophil Accumulation in a Murine Model of Peritonitis , 2000, The Journal of experimental medicine.

[28]  GISSI-Prevenzione Investigators,et al.  Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial , 1999, The Lancet.

[29]  Takao Shimizu,et al.  A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis , 1997, Nature.

[30]  M. Perretti,et al.  Inhibition of neutrophil and monocyte recruitment by endogenous and exogenous lipocortin 1 , 1997, British journal of pharmacology.

[31]  S. Dahlén,et al.  Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. , 1987, Science.

[32]  E. Goetzl,et al.  Heterogeneity of Human Polymorphonuclear Leukocyte Receptors for Leukotriene B4 Identification of a Subset of High Affinity Receptors That Transduce the Chemotactic Response , 1980 .